Clinical Trial Update: Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial comparing osimertinib versus docetaxel-bevacizumab as third-line therapy for EGFR T790M-mutated non-small cell lung cancer has completed Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Docetaxel-bevacizumab
• Osimertinib (osimertinib)

Snippet

Sponsor: Qingdao Central Hospital | Conditions: Progression Free Survival | Phase 2, Phase 3 | Status: COMPLETED